Shares Outstanding Shares Outstanding n/a Close	124.85M
Shares Change (YoY) Shares Change (YoY) n/a Close	2.17%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	1.03%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	87.07%
Shares Floating Shares Floating n/a Close	118.71M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	340
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.01%

Short Selling Information

The latest short interest is 13.43M, so 10.91% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	13.43M
Short % of Shares Out Short % of Shares Out n/a Close	10.91%
Short % of Float Short % of Float n/a Close	18.09%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	3.14

Valuation Ratios

The PE ratio is -9.47 and the forward PE ratio is -12.47. 10x Genomics's PEG ratio is 0.31.

PE Ratio PE Ratio n/a Close	-9.47
Forward PE Forward PE n/a Close	-12.47
PS Ratio PS Ratio n/a Close	2.83
Forward PS Forward PS n/a Close	2
PB Ratio PB Ratio n/a Close	2.44
P/FCF Ratio P/FCF Ratio n/a Close	-301.92
PEG Ratio PEG Ratio n/a Close	0.31

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for 10x Genomics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.

Current Ratio Current Ratio n/a Close	4.97
Quick Ratio Quick Ratio n/a Close	4.26
Debt / Equity Debt / Equity n/a Close	0.12
Debt / EBITDA Debt / EBITDA n/a Close	-0.62
Debt / FCF Debt / FCF n/a Close	-14.42
Interest Coverage Interest Coverage n/a Close	-48639.75

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$467,676.11
Profits Per Employee Profits Per Employee n/a Close	$-139,836.91
Employee Count Employee Count n/a Close	1,306
Asset Turnover Asset Turnover n/a Close	0.66
Inventory Turnover Inventory Turnover n/a Close	2.36

Taxes

Income Tax Income Tax n/a Close	4.93M
Effective Tax Rate Effective Tax Rate n/a Close	-2.77%

Stock Price Statistics

The stock price has increased by -39.74% in the last 52 weeks. The beta is 1.98, so 10x Genomics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.98
52-Week Price Change 52-Week Price Change n/a Close	-39.74%
50-Day Moving Average 50-Day Moving Average n/a Close	9.3
200-Day Moving Average 200-Day Moving Average n/a Close	13.27
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	69.98
Average Volume (20 Days) Average Volume (20 Days) n/a Close	3,856,588

Income Statement

In the last 12 months, 10x Genomics had revenue of 610.78M and earned -182.63M in profits. Earnings per share was -1.52.

Revenue Revenue n/a Close	610.78M
Gross Profit Gross Profit n/a Close	414.48M
Operating Income Operating Income n/a Close	-194.56M
Net Income Net Income n/a Close	-182.63M
EBITDA EBITDA n/a Close	-133.99M
EBIT EBIT n/a Close	-177.7M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-1.52

Full Income Statement

Balance Sheet

The company has 344.07M in cash and 82.61M in debt, giving a net cash position of 261.45M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	344.07M
Total Debt Total Debt n/a Close	82.61M
Net Cash Net Cash n/a Close	261.45M
Retained Earnings Retained Earnings n/a Close	-1.47B
Total Assets Total Assets n/a Close	903.39M
Working Capital Working Capital n/a Close	471.83M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.66M and capital expenditures -12.39M, giving a free cash flow of -5.73M.

Operating Cash Flow Operating Cash Flow n/a Close	6.66M
Capital Expenditures Capital Expenditures n/a Close	-12.39M
Free Cash Flow Free Cash Flow n/a Close	-5.73M
FCF Per Share FCF Per Share n/a Close	-0.05

Full Cash Flow Statement

Margins

Gross margin is 67.86%, with operating and profit margins of -31.85% and -29.9%.

Gross Margin Gross Margin n/a Close	67.86%
Operating Margin Operating Margin n/a Close	-31.85%
Pretax Margin Pretax Margin n/a Close	-29.09%
Profit Margin Profit Margin n/a Close	-29.9%
EBITDA Margin EBITDA Margin n/a Close	-21.94%
EBIT Margin EBIT Margin n/a Close	-31.85%
FCF Margin FCF Margin n/a Close	-0.94%

Dividends & Yields

TXG does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for TXG is $14, which is 19.5% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$14
Price Target Difference Price Target Difference n/a Close	19.5%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jul 17, 2006. It was a backward split with a ratio of 1:2.

Last Split Date Last Split Date n/a Close	Jul 17, 2006
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:2

Scores

Altman Z-Score Altman Z-Score n/a Close	1.58
Piotroski F-Score Piotroski F-Score n/a Close	5